The recently diagnosed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in December 2019 commonly affects the respiratory system. The incidence of acute hypoxic respiratory failure varied among epidemiological studies with high percentage of patients requiring mechanical ventilation with a high mortality. Noninvasive ventilation is an alternative tool for ventilatory support instead of invasive mechanical ventilation, especially with scarce resources and intensive care beds. Initially, there were concerns by the national societies regarding utilization of noninvasive ventilation in acute respiratory failure. Recent publications reflect the gained experience with the safe utilization of noninvasive mechanical ventilation. Noninvasive ventilation has beneficiary role in treatment of acute hypoxic respiratory failure with proper indications, setting, monitoring, and timely escalation of therapy. Patients should be monitored frequently for signs of improvement or deterioration in the clinical status. Awareness of indications, contraindications, and parameters reflecting either success or failure of noninvasive ventilation in the management of acute respiratory failure secondary to COVID-19 is essential for improvement of outcomes.

中文翻译：

---

无创通气治疗呼吸衰竭相关 COVID-19 感染：文献回顾

最近确诊的 2019 年冠状病毒病 (COVID-19) 是由 2019 年 12 月的严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 引起的，通常会影响呼吸系统。在流行病学研究中，急性缺氧性呼吸衰竭的发生率各不相同，需要机械通气的患者比例很高，死亡率很高。无创通气是替代有创机械通气的通气支持的替代工具，尤其是在资源和重症监护病床稀缺的情况下。最初，国家学会担心在急性呼吸衰竭中使用无创通气。最近的出版物反映了在安全使用无创机械通气方面获得的经验。无创通气在治疗急性缺氧性呼吸衰竭中具有有益的作用，具有适当的适应症、设置、监测和及时的治疗升级。应经常监测患者临床状况的改善或恶化迹象。了解无创通气治疗继发于 COVID-19 的急性呼吸衰竭的适应症、禁忌症和参数对于改善预后至关重要。